Kartagener Syndrome Cell Models for Research

Kartagener Syndrome (KS) is a rare autosomal recessive disorder characterized by the triad of chronic sinusitis, bronchiectasis, and situs inversus. It is a subtype of primary ciliary dyskinesia (PCD), with an estimated prevalence of 1 in 30,000 live births (WHO, 2023). The condition results from defective ciliary motility, leading to impaired mucociliary clearance, chronic respiratory infections, and progressive lung damage. Situs inversus occurs in about 50% of PCD cases due to randomization of left-right body asymmetry. There is no cure, and management focuses on symptomatic treatment and infection control. The 5-year survival is not typically reported for KS, but respiratory failure is a major cause of morbidity and mortality in adulthood (NCI, 2023).

KS serves as an excellent model for studying ciliary biology, mucociliary clearance, and the molecular mechanisms underlying left-right patterning. The disease is monogenic in many cases, with mutations in genes encoding axonemal dynein components, making it amenable to gene editing. Public datasets, such as those from the Genomics England PanelApp and ClinVar, provide curated lists of disease-causing variants. Open questions include the genotype-phenotype correlation, the role of modifier genes, and the development of targeted therapies to restore ciliary function.

Kartagener Syndrome is not a cancer, but the chronic inflammation and recurrent infections can lead to metaplastic changes in the respiratory epithelium. The key pathways involved in the pathogenesis include:

• • Defects in axonemal dynein assembly and function, leading to immotile cilia.
• • Impaired mucociliary clearance, causing chronic bacterial colonization and neutrophil-dominated inflammation.
• • Activation of the NF-κB pathway in response to chronic infection, leading to tissue remodeling and bronchiectasis.
• • Dysregulation of the TGF-β signaling pathway, contributing to fibrosis and airway remodeling.

Mutations in several genes are known to cause Kartagener Syndrome. The most frequently mutated genes are listed below, with data from ClinVar and the PCD mutation database (not TCGA/COSMIC, as these are not cancer-related).

Although KS is not a cancer, the chronic inflammatory state activates several signaling networks:

• • NF-κB pathway: Activated by bacterial products and inflammatory cytokines, leading to expression of pro-inflammatory genes.
• • TGF-β pathway: Involved in airway remodeling and fibrosis, with increased expression of TGF-β1 in bronchiectatic tissue.
• • Wnt pathway: Altered in the context of mucociliary clearance, potentially affecting epithelial regeneration.
• • Notch pathway: Regulates ciliated cell differentiation; dysregulation may contribute to abnormal ciliary function.

Several cell lines are used to study ciliary function and Kartagener Syndrome. The table below lists common cell lines and their origins.

Organoids derived from patient iPSCs or nasal epithelial cells are increasingly used to model ciliary dysfunction in a 3D context, allowing for drug screening and mechanistic studies.

Animal models for Kartagener Syndrome are primarily mouse models with targeted mutations in dynein genes. Examples include:

• • DNAH5 knockout mice: Exhibit hydrocephalus, sinusitis, and situs inversus.
• • DNAI1 knockout mice: Show reduced ciliary beat frequency and chronic respiratory infections.
• • CCDC39 mutant mice: Display ciliary disorganization and impaired mucociliary clearance.

These models are valuable for studying disease pathogenesis and testing therapeutic interventions. Patient-derived xenografts (PDX) are not applicable for this non-cancer disease.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific mutations in genes such as DNAH5, DNAI1, or CCDC39. These models are essential for dissecting the functional consequences of individual mutations and for drug discovery. For example:

• • A DNAH5 knockout cell line can be generated in a ciliated epithelial cell background to study the impact on ciliary beat frequency and mucociliary clearance.
• • A knock-in cell line carrying a specific missense mutation (e.g., DNAH5 p.Arg1234Cys) can be used to evaluate the effect on protein function and response to potential therapies.

Commercially available, sequence-verified gene-edited cell lines accelerate research by providing consistent and reproducible models. These are available from various sources, but specific companies are not named here.

Gene-edited cell lines are used to validate the function of genes implicated in Kartagener Syndrome. For example, knocking out DNAH5 in a ciliated cell line and observing loss of ciliary motility confirms its role. Similarly, introducing a patient-specific mutation into a wild-type cell line can establish causality. These models are also used in high-throughput screens to identify genetic modifiers that rescue ciliary function.

Isogenic pairs (wild-type vs. mutant) are valuable for drug screening. For instance, a DNAH5 knockout cell line can be used to test compounds that aim to restore ciliary beat frequency or improve mucociliary clearance. Additionally, gene-edited models can be used to study the development of resistance to therapies, such as antibiotics, in the context of chronic infections.

CRISPR-based screens can identify synthetic lethal interactions or biomarkers of disease severity. For example, a genome-wide CRISPR knockout screen in a DNAH5-deficient cell line could reveal genes whose loss exacerbates or rescues the ciliary defect, providing potential therapeutic targets or biomarkers.